+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 4Years +
All Genders
ID07538583

Open-Label Study of QRX003 Lotion Applied Twice Daily to Treat Netherton Syndrome in Participants Aged 4 Years and Older

Led by Quoin Pharmaceuticals · Updated on 2026-09-28

16

Participants Needed

8

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and effectiveness of QRX003 lotion, a 4% serine protease inhibitor, in treating Netherton syndrome NS. This study focuses on applying the lotion twice daily to affected skin areas excluding the scalp, covering about 50% or more of the body surface. The trial is conducted at multiple centers and follows an open-label design, including participants aged 4 years and older with genetically confirmed NS. Participants will apply QRX003 lotion twice daily for 12 weeks to their NS-affected skin areas. The treatment area excludes the scalp and covers approximately half or more of the body surface. This single-group study does not include a placebo or comparator group. The study spans 12 weeks of active treatment with the lotion. During the trial, participants will be monitored for improvement using several measures, including the Investigator Global Assessment IGA score to track skin condition changes, and other itch and global impression scores at week 12. Safety and tolerability will also be assessed throughout the treatment period. The total participation duration aligns with the 12-week treatment, with follow-up evaluations at the studys end.

CONDITIONS

Brief Title

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Research Team

T

TI Clinical Research

L

Lisa Duarte

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here